2026-01-18 - Analysis Report
# Financial Report: Amgen Inc. (AMGN)

## Company Overview
Biotechnology company that discovers, develops, manufactures, and distributes medicines for serious illnesses.

## Comparison with S&P 500 (VOO)
* Cumulative return of AMGN: 71.01%
* Cumulative return of VOO: 93.36%
* Degree of divergence: -22.70

## Alpha, Beta Analysis
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|-----|------|-----|-------|------|-------|
| 2016-2018 | 14.0% | 14.6% | 11.0% | 1.1 | 104.8B |
| 2017-2019 | 41.0% | 12.4% | 24.0% | 0.9 | 129.8B |
| 2018-2020 | 8.0% | 17.7% | -13.0% | 0.8 | 123.8B |
| 2019-2021 | 15.0% | 17.7% | -28.0% | 0.8 | 121.1B |
| 2020-2022 | 15.0% | 15.5% | 17.0% | 0.6 | 141.4B |
| 2021-2023 | 19.0% | 15.3% | 19.0% | 0.4 | 155.1B |
| 2022-2024 | 12.0% | 21.0% | -8.0% | 0.4 | 140.3B |
| 2023-2025 | 38.0% | 21.0% | -24.0% | 0.5 | 176.2B |

## Recent Stock Price Fluctuations
* Close: $330.41
* Last-market change: $0.12
* 5-day SMA: $327.85
* 20-day SMA: $329.14
* 60-day SMA: $324.51

## RSI, PPO, and Delta_Previous_Relative_Divergence Analysis
* Market Risk Indicator (MRI): 0.80
* RSI: 47.80
* PPO: -0.04
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.80)
* Expected Return (%): -2.10%
* Recent (20 days) relative divergence change: -1.10 (worsening)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.00 (flat)

## Recent News & Significant Events
* [2026-01-17] Amgen Inc. $AMGN Stock Position Cut by QRG Capital Management Inc. - MarketBeat (news.google.com)
* [2026-01-17] Assessing Amgen (AMGN) Valuation As Shares Track Close To Analyst Targets - simplywall.st (news.google.com)
* [2026-01-14] Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance (news.google.com)
* [2026-01-07] Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more - CNBC (news.google.com)
* [2026-01-13] Amgen Stock (AMGN) Falls despite Obesity Drug Update — Here’s Wall Street’s Take - TipRanks (news.google.com)
* [2026-01-13] BofA Securities raises Amgen stock price target to $304 on valuation shift - Investing.com (news.google.com)

## Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.34 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 331.59 / 425.00 / 180.00

## Recent Earnings Analysis
| Date | EPS | Revenue |
|-----|---:|-------|
| 2025-11-05 | 5.98 | $9.56 B |
| 2025-08-06 | 2.66 | $9.18 B |
| 2025-05-02 | 3.22 | $8.15 B |
| 2024-10-31 | 5.27 | $8.50 B |

## Financial Information: Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

## Financial Information: Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

## Comprehensive Analysis (Summary of previous items)
Based on the provided data, Amgen Inc. (AMGN) has a cumulative return of 71.01%, lower than the S&P 500 (VOO) at 93.36%. The degree of divergence is -22.70. The Alpha, Beta analysis shows mixed results across different time periods. The recent stock price fluctuations indicate a slight increase, but the RSI and PPO indicate a bearish trend. The Market Risk Indicator is 0.80, indicating a medium risk level. The Expected Return is -2.10%. The recent news and significant events show mixed opinions on the company's performance. The analyst opinions suggest a buy recommendation with a target price of $331.59. The recent earnings analysis indicates strong EPS growth. The financial information shows high revenue and profit margins, as well as a significant increase in equity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.